Published in Vaccine Weekly, November 27th, 2002
This decision was made based on a recommendation from an independent review of interim data from their double-blinded randomized trial conducted in 1030 women with metastatic breast cancer. Theratope vaccine has fast-track designation with the U.S. Food and Drug Administration (FDA) for the treatment of metastatic breast cancer.
The Data Safety Monitoring board (DSMB) stated that they had "no safety concerns at all and recommend that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.